Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27, H1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results

Date of Board Meeting / Approval: November 12, 2026

Audit Opinion: Clean (Limited Review Report with no modifications)

Auditor’s Comment: The statutory auditors, NSVR & Associates LLP, conducted a limited review and stated that nothing has come to their attention to believe the statement contains any material misstatements.

Key Financial Highlights [Amounts in INR Lakh]

Standalone Results:

Revenue from Operations:

  • Q2 FY27: ₹1,418.30 lakh (vs. Q2 FY26: ₹1,039.32 lakh | YoY: +36.4%)
  • H1 FY27: ₹2,486.13 lakh (vs. H1 FY26: ₹1,741.95 lakh | YoY: +42.7%)

Total Income:

  • Q2 FY27: ₹1,420.15 lakh
  • H1 FY27: ₹2,488.78 lakh

Net Profit:

  • Q2 FY27: ₹11.58 lakh (vs. Q2 FY26: Net Loss of ₹(53.00) lakh)
  • H1 FY27: ₹163.01 lakh (vs. H1 FY26: Net Loss of ₹(46.51) lakh)

EPS (Basic) [Not annualized]:

  • Q2 FY27: ₹0.06
  • H1 FY27: ₹0.85

Other Equity:

  • As of September 30, 2026: ₹2,802.57 lakh
  • As of March 31, 2026: ₹2,639.57 lakh

Cash and Cash Equivalents:

  • As of September 30, 2026: ₹1,130.51 lakh
  • As of March 31, 2026: ₹1,669.52 lakh

Debt:

Total Borrowings (Non-current + Current):

  • As of September 30, 2026: ₹5,243.15 lakh (Non-current: ₹1,706.02 lakh, Current: ₹3,537.13 lakh)
  • As of March 31, 2026: ₹4,532.54 lakh (Non-current: ₹1,020.66 lakh, Current: ₹3,511.88 lakh)

Segment-wise Performance:

The company operates in one reportable business segment: Active pharmaceutical ingredients and intermediates. Segmental reporting as per Ind AS 108 is not applicable.

Corporate Actions:

Not Specified

Other Significant Information:

Entities included/excluded in consolidation: Standalone results only.

Exceptional items: There were no exceptional items for any of the periods presented.

Change in accounting policy: Earnings per share for periods prior to the rights issue (allotted on February 2, 2026) have been restated for the bonus element of the rights issue in accordance with Ind AS 33. EPS for the quarter ended June 30, 2026, has been recomputed on the paid-up shares of 1,92,06,266.

Statement of Assets and Liabilities (Standalone) as at September 30, 2026 [INR Lakh]:

  • Total Assets: ₹13,815.53 lakh (Mar-26: ₹12,478.34 lakh)
  • Total Equity: ₹4,723.20 lakh (Mar-26: ₹4,560.19 lakh)
  • Inventories: ₹7,472.71 lakh (Mar-26: ₹6,400.07 lakh)
  • Trade Receivables: ₹1,477.98 lakh (Mar-26: ₹1,139.91 lakh)

Statement of Cash Flows (Standalone) for H1 FY27 [INR Lakh]:

  • Net Cash from Operating Activities: ₹(863.39) lakh (H1 FY26: ₹(1,224.47) lakh)
  • Net Cash used in Investing Activities: ₹(255.00) lakh (H1 FY26: ₹(111.00) lakh)
  • Net Cash from Financing Activities: ₹579.38 lakh (H1 FY26: ₹2,974.34 lakh)
  • Primary use of cash in operations was an increase in inventories (₹1,063.64 lakh) and trade receivables (₹338.07 lakh).